Clinical trials: Hemostatic Agents
Generalized Arterial Calcification of Infancy, Autosomal Recessive Hypophosphatemic Rickets Type2
Study of People With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2)
Background: Generalized Arterial Calcification of Infancy (GACI) is a very rare disorder. It can be fatal before birth or by age 6 months. Anumber of people with GACI survive into adulthood.
- Trial name
- NCT03478839
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Cerebral Cavernous Malformation, Intracerebral Hemorrhage
CoHOrt of Cerebral CavernOus maLformATion: multicEnter Prospective Observational Study
The aim of this prospective study is to reveal the natural history of symptomatic hemorrhage in adult patients with cerebral cavernous malformation with the goal of informing the treatment plan.
- Trial name
- CHOCOOATE (NCT02946866)
- Where
- 8 sites in South Korea
- Volunteers
- 228 people
- Sponsor
- Seoul National University Hospital
Myeloma, Plasma-Cell, Lymphoma, Malignant
Multi-day Doses in Prevention of Nausea and Emesis
To assess emetic responses to multi-day doses of Palonosetron and Aprepitant and low dose dexamethasone +/- Prochlorperazine among patients with multiple myeloma and lymphoma undergoing autologous HSCT utilizing the Multinational…
- Trial name
- NCT00600353
- Testing
- Palonosetron, Aprepitant, Dexamethasone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Kansas Medical Center
Multiple Myeloma, Secondary Immunodeficiency (SID)
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
In this study, multiple myeloma participants with secondary immunodeficiency (SID) will be treated with HyQvia according to their clinic's standard practice.
- Trial name
- NCT05879757
- Testing
- No Intervention
- Where
- 27 sites in Argentina, Czechia and 9 more
- Volunteers
- 75 people
- Sponsor
- Takeda
Multiple Myeloma
Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma
This study aims to evaluate the stringent Complete Response (sCR) rate by the end of two cycles of induction treatment, defined as the proportion of patients who have achieved sCR, according to International Myeloma Working Group…
- Trial name
- Isa-RVD (NCT05123131)
- Testing
- Isatuximab, Bortezomib, Lenalidomide
- Where
- 5 sites in Denmark, Ireland
- Volunteers
- 54 people
- Sponsor
- Cancer Trials Ireland
Coagulation Disorder
Effect of Aerobic Exercises on Sex Hormones and Coagulation Factors in Postmenopausal Elderly Women
PURPOSE: to determine the effect of aerobic exercise training on sex hormones and coagulation factors in postmenopausal elderly women BACKGROUND: Cardiovascular disease (CVD) is the largest cause of death in women, and the risk…
- Trial name
- NCT04488341
- Testing
- aerobic exercises in addition to diet recommendations, diet recommendations
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Extramedullary Disease in Multiple Myeloma, Multiple Myeloma
External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
This phase I/II trial tests the safety and effectiveness of extramedullary disease (EMD)-directed external beam radiation therapy (EBRT) in combination with talquetamab for the treatment of multiple myeloma patients with…
- Trial name
- NCT06572605
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
Quality of Life in Patients With Multiple Myeloma-validation Study
In this study, the Myeloma Patient Outcome Scale (MyPOS) will be translated from English to German. This translated version will be quantitatively and qualitatively validated with patients with multiple myeloma.
- Trial name
- NCT03537222
- Testing
- Myeloma Patient Outcome Scale (MyPOS)
- Where
- 3 sites in Switzerland
- Volunteers
- 58 people
- Sponsor
- Zurich University of Applied Sciences
Multiple Myeloma
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
The study is designed as a Phase II, multicenter trial of vaccination with Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide maintenance therapy versus…
- Trial name
- NCT02728102
- Testing
- Tumor Cell Collection, Autologous Stem Cell Transplant, Melphalan
- Where
- 15 sites in United States
- Volunteers
- 203 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Recurrent Plasma Cell Myeloma, T(11;14)
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma
This phase I trial studies the side effects and best dose of venetoclax when given together with ixazomib citrate and dexamethasone and to see how well they work in treating patients with multiple myeloma that has come back.
- Trial name
- NCT03399539
- Testing
- Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Relapsed or Refractory Multiple Myeloma
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
This was a multicenter, open-label, single-arm phase 3B study of the combination lenalidomide plus pulse high-dose dexamethasone.
- Trial name
- NCT00478777
- Testing
- Lenalidomide, dexamethasone
- Where
- 48 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Celgene Corporation
Multiple Myeloma, Bone Metastases
Evaluation of Whole Body Examination by MRI Integrating the "Zero Time Eco" Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body Scanner
To assess the added value of magnetic resonance imaging (MRI) of the skeleton compared to other validated techniques for the detection of bone lesions in patients with multiple myeloma.
- Trial name
- MM-ZTE (NCT05381077)
- Testing
- MRI
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Multiple Myeloma
Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with Multiple Myeloma (MM) who have had an Autologous Hematopoietic Stem Cell Transplant (AHCT) and have already had…
- Trial name
- NCT05354557
- Testing
- Iberdomide
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
This study is a open-label, single-center Phase 2 study to evaluate the efficacy and safety of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT.
- Trial name
- NCT05846737
- Testing
- anti-BCMA CAR-T
- Where
- China
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma, Quality of Life
Quality of Life in Patients With Multiple Myeloma
The purpose of this study is to determine Clinically important difference and Response shift in quality of life in patients with Multiple Myeloma.
- Trial name
- NCT00290095
- Where
- Norway
- Volunteers
- 260 people
- Sponsor
- Ullevaal University Hospital
Multiple Myeloma
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma
Toward improving the therapeutic index of standard TT3 (S-TT3), the investigators will employ a randomized Phase III trial design to determine whether S-TT3 treatment-related toxicities can be reduced by 50% in TT3-Lite (L-TT3).
- Trial name
- TT4B (NCT00734877)
- Testing
- M-VTD-PACE, TT3-LITE Regimen (L-TT3)
- Where
- United States
- Volunteers
- 382 people
- Sponsor
- University of Arkansas
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
This phase II MATCH treatment trial tests how well sunitinib in treating patients with cancer that has certain genetic changes. Sunitinib is in a class of medications called kinase inhibitors.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06390826
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Pain
Analgetic Effectiveness of a Lidocaine Loaded Hemostatic, Bioresorbable Putty
The goal of this study was to test the efficacy of local analgesic (lidocaine) loaded hemostatic putty in reducing donor site pain following the harvest of pelvic bone grafts.
- Trial name
- NCT01504035
- Testing
- Orthostat-L, Orthostat
- Where
- Switzerland
- Volunteers
- 14 people
- Sponsor
- University Hospital, Basel, Switzerland
Multiple Myeloma, Plasma Cell Neoplasm
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00075608
- Testing
- filgrastim, melphalan, autologous stem cell transplantation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Boston Medical Center
Women With Coagulation Disorders
Effect of Ginger on Heavy Menstrual Bleeding in Women With Coagulation Disorders
The GINGER-BLEED study is a randomized, double-blind, placebo-controlled clinical trial evaluating the effect of ginger powder on heavy menstrual bleeding in women with coagulopathies.
- Trial name
- GINGER-BLEED (NCT07595640)
- Testing
- Ginger
- Volunteers
- 74 people
- Sponsor
- University of Valladolid
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.